- Home
- SQNS vs CUE Comparison
SQNS vs CUE Comparison
Compare SQNS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQNS | CUE |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 233.5M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SQNS | CUE |
|---|---|---|
| Price | $2.74 | $25.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $10.00 | ★ $88.00 |
| AVG Volume (30 Days) | 35.4K | ★ 353.1K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $66.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $2.38 | $0.17 |
| 52 Week High | $10.19 | $45.50 |
Technical Indicators
Market Signals| Indicator | SQNS | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 42.64 |
| Support Level | $2.72 | $23.51 |
| Resistance Level | $3.19 | $33.11 |
| Average True Range (ATR) | 0.17 | 4.91 |
| MACD | -0.02 | -0.83 |
| Stochastic Oscillator | 1.20 | 11.41 |
Price Performance
Historical ComparisonAbout SQNS Sequans Communications S.A.
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.